CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (UNAUDITED) - USD ($) $ in Thousands |
Total |
Stockholders’ (Deficit) Equity |
Common Stock |
Additional Paid-In Capital |
Accumulated Deficit |
Accumulated Other Comprehensive Income (Loss) |
Treasury stock, at cost |
Non-controlling interest |
Balance at Dec. 31, 2022 |
$ 103,864
|
$ 100,017
|
$ 12
|
$ 787,130
|
$ (688,492)
|
$ 1,371
|
$ (4)
|
$ 3,847
|
Balance (in Shares) at Dec. 31, 2022 |
|
|
106,417,265
|
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
Vesting of RSUs (in shares) |
|
|
619,387
|
|
|
|
|
|
Issuance of RSAs (in shares) |
|
|
27,744
|
|
|
|
|
|
Exercise of common stock options |
25
|
25
|
|
25
|
|
|
|
|
Exercise of common stock options (in Shares) |
|
|
91,258
|
|
|
|
|
|
Stock-based compensation expense |
4,548
|
4,548
|
|
4,548
|
|
|
|
|
Net loss |
(16,349)
|
(16,349)
|
|
|
(16,349)
|
|
|
|
Foreign currency translation adjustment |
432
|
432
|
|
|
|
432
|
|
|
Balance at Mar. 31, 2023 |
92,520
|
88,673
|
$ 12
|
791,703
|
(704,841)
|
1,803
|
(4)
|
3,847
|
Balance (in Shares) at Mar. 31, 2023 |
|
|
107,155,654
|
|
|
|
|
|
Balance at Dec. 31, 2022 |
103,864
|
100,017
|
$ 12
|
787,130
|
(688,492)
|
1,371
|
(4)
|
3,847
|
Balance (in Shares) at Dec. 31, 2022 |
|
|
106,417,265
|
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
Net loss |
(55,339)
|
|
|
|
|
|
|
|
Foreign currency translation adjustment |
(218)
|
|
|
|
|
|
|
|
Balance at Sep. 30, 2023 |
84,105
|
80,258
|
$ 12
|
822,928
|
(743,831)
|
1,153
|
(4)
|
3,847
|
Balance (in Shares) at Sep. 30, 2023 |
|
|
108,976,312
|
|
|
|
|
|
Balance at Mar. 31, 2023 |
92,520
|
88,673
|
$ 12
|
791,703
|
(704,841)
|
1,803
|
(4)
|
3,847
|
Balance (in Shares) at Mar. 31, 2023 |
|
|
107,155,654
|
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
Vesting of RSUs (in shares) |
|
|
605,975
|
|
|
|
|
|
Issuance of RSAs (in shares) |
|
|
376,325
|
|
|
|
|
|
Exercise of common stock options |
13
|
13
|
|
13
|
|
|
|
|
Exercise of common stock options (in Shares) |
|
|
46,583
|
|
|
|
|
|
Stock-based compensation expense |
3,697
|
3,697
|
|
3,697
|
|
|
|
|
Issuance of common warrants |
14,598
|
14,598
|
|
14,598
|
|
|
|
|
Net loss |
(15,770)
|
(15,770)
|
|
|
(15,770)
|
|
|
|
Foreign currency translation adjustment |
20
|
20
|
|
|
|
20
|
|
|
Balance at Jun. 30, 2023 |
95,078
|
91,231
|
$ 12
|
810,011
|
(720,611)
|
1,823
|
(4)
|
3,847
|
Balance (in Shares) at Jun. 30, 2023 |
|
|
108,184,537
|
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
Vesting of RSUs (in shares) |
|
|
260,215
|
|
|
|
|
|
Issuance of RSAs (in shares) |
|
|
24,500
|
|
|
|
|
|
Exercise of common stock options |
28
|
28
|
|
28
|
|
|
|
|
Exercise of common stock options (in Shares) |
|
|
98,829
|
|
|
|
|
|
Stock-based compensation expense |
3,762
|
3,762
|
|
3,762
|
|
|
|
|
Exercise of common warrants |
882
|
882
|
|
882
|
|
|
|
|
Exercise of common warrants (in shares) |
|
|
408,231
|
|
|
|
|
|
Issuance of common warrants |
8,245
|
8,245
|
|
8,245
|
|
|
|
|
Net loss |
(23,220)
|
(23,220)
|
|
|
(23,220)
|
|
|
|
Foreign currency translation adjustment |
(670)
|
(670)
|
|
|
|
(670)
|
|
|
Balance at Sep. 30, 2023 |
84,105
|
80,258
|
$ 12
|
822,928
|
(743,831)
|
1,153
|
(4)
|
3,847
|
Balance (in Shares) at Sep. 30, 2023 |
|
|
108,976,312
|
|
|
|
|
|
Balance at Dec. 31, 2023 |
80,096
|
78,734
|
$ 12
|
837,416
|
(760,227)
|
2,198
|
(665)
|
1,362
|
Balance (in Shares) at Dec. 31, 2023 |
|
|
111,132,222
|
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
Vesting of RSUs (in shares) |
|
|
1,226,498
|
|
|
|
|
|
Issuance of RSAs (in shares) |
|
|
38,130
|
|
|
|
|
|
Exercise of common stock options |
544
|
544
|
|
544
|
|
|
|
|
Exercise of common stock options (in Shares) |
|
|
186,074
|
|
|
|
|
|
Reclassification of warrant liability to common stock warrants |
2,468
|
2,468
|
|
2,468
|
|
|
|
|
Stock-based compensation expense |
6,293
|
6,293
|
|
6,293
|
|
|
|
|
Net loss |
(31,610)
|
(31,610)
|
|
|
(31,610)
|
|
|
|
Foreign currency translation adjustment |
(522)
|
(522)
|
|
|
|
(522)
|
|
|
Balance at Mar. 31, 2024 |
57,269
|
55,907
|
$ 12
|
846,721
|
(791,837)
|
1,676
|
(665)
|
1,362
|
Balance (in Shares) at Mar. 31, 2024 |
|
|
112,582,924
|
|
|
|
|
|
Balance at Dec. 31, 2023 |
80,096
|
78,734
|
$ 12
|
837,416
|
(760,227)
|
2,198
|
(665)
|
1,362
|
Balance (in Shares) at Dec. 31, 2023 |
|
|
111,132,222
|
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
Net loss |
(69,609)
|
|
|
|
|
|
|
|
Foreign currency translation adjustment |
304
|
|
|
|
|
|
|
|
Balance at Sep. 30, 2024 |
65,571
|
65,571
|
$ 14
|
893,584
|
(829,836)
|
2,502
|
(693)
|
|
Balance (in Shares) at Sep. 30, 2024 |
|
|
127,545,321
|
|
|
|
|
|
Balance at Mar. 31, 2024 |
57,269
|
55,907
|
$ 12
|
846,721
|
(791,837)
|
1,676
|
(665)
|
1,362
|
Balance (in Shares) at Mar. 31, 2024 |
|
|
112,582,924
|
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
Vesting of RSUs |
1
|
1
|
$ 1
|
|
|
|
|
|
Vesting of RSUs (in shares) |
|
|
294,589
|
|
|
|
|
|
Issuance of RSAs (in shares) |
|
|
231,323
|
|
|
|
|
|
Exercise of common stock options |
1,106
|
1,106
|
|
1,106
|
|
|
|
|
Exercise of common stock options (in Shares) |
|
|
438,118
|
|
|
|
|
|
Reclassification of warrant liability to common stock warrants |
4,308
|
4,308
|
|
4,308
|
|
|
|
|
Stock-based compensation expense |
2,792
|
2,792
|
|
2,792
|
|
|
|
|
Exercise of common warrants |
21,036
|
21,036
|
$ 1
|
21,035
|
|
|
|
|
Exercise of common warrants (in shares) |
|
|
9,738,930
|
|
|
|
|
|
Interest payment through issuance of shares of common stock |
1,867
|
1,867
|
|
1,867
|
|
|
|
|
Interest payment through issuance of shares of common stock (in Shares) |
|
|
237,722
|
|
|
|
|
|
Redemption of NCI |
67
|
1,429
|
|
1,429
|
|
|
|
(1,362)
|
Redemption of NCI (in Shares) |
|
|
397,037
|
|
|
|
|
|
Shares of Common Stock received from settlement of employee receivables |
(28)
|
(28)
|
|
|
|
|
(28)
|
|
Net loss |
(24,390)
|
(24,390)
|
|
|
(24,390)
|
|
|
|
Foreign currency translation adjustment |
(179)
|
(179)
|
|
|
|
(179)
|
|
|
Balance at Jun. 30, 2024 |
63,849
|
63,849
|
$ 14
|
879,258
|
(816,227)
|
1,497
|
(693)
|
|
Balance (in Shares) at Jun. 30, 2024 |
|
|
123,917,627
|
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
Shares of Common Stock received from settlement of employee receivables (in Shares) |
|
|
(3,016)
|
|
|
|
|
|
Vesting of RSUs (in shares) |
|
|
243,481
|
|
|
|
|
|
Exercise of common stock options |
232
|
232
|
|
232
|
|
|
|
|
Exercise of common stock options (in Shares) |
|
|
207,977
|
|
|
|
|
|
Reclassification of warrant liability to common stock warrants |
4,747
|
4,747
|
|
4,747
|
|
|
|
|
Stock-based compensation expense |
2,487
|
2,487
|
|
2,487
|
|
|
|
|
Exercise of common warrants |
6,860
|
6,860
|
|
6,860
|
|
|
|
|
Exercise of common warrants (in shares) |
|
|
3,176,236
|
|
|
|
|
|
Redemption of NCI |
|
|
$ (1,400)
|
|
|
|
|
|
Redemption of NCI (in Shares) |
|
|
397,037
|
|
|
|
|
|
Net loss |
(13,609)
|
(13,609)
|
|
|
(13,609)
|
|
|
|
Foreign currency translation adjustment |
1,005
|
1,005
|
|
|
|
1,005
|
|
|
Balance at Sep. 30, 2024 |
$ 65,571
|
$ 65,571
|
$ 14
|
$ 893,584
|
$ (829,836)
|
$ 2,502
|
$ (693)
|
|
Balance (in Shares) at Sep. 30, 2024 |
|
|
127,545,321
|
|
|
|
|
|